Human Integrin alpha 4 beta 7/LPAM-1 (Research Grade Vedolizumab Biosimilar) Antibody

Name: Human Integrin alpha 4 beta 7/LPAM-1 (Research Grade Vedolizumab Biosimilar) Antibody
Brand: R&D Systems
SKU: MAB10078
Rating: 4 (1 reviews)

Catalog #: MAB10078
2 Citations 1 Review Datasheet / COA / SDS

Recombinant Monoclonal Antibody For Research Use Only

Catalog #	Availability	Size / Price	Qty
MAB10078-100
MAB10078-SP

Detection of Integrin alpha 4 beta 7/LPAM‑1 in Human PBMC by Flow Cytometry.

2 Images

All Integrin alpha 4 beta 7/LPAM-1 Antibodies

Product Details

Citations (2)

FAQs

Supplemental Products

Reviews (1)

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human Integrin alpha 4 beta 7/LPAM-1 (Research Grade Vedolizumab Biosimilar) Antibody Summary

Species Reactivity

Human

Specificity

Detects human Integrin alpha 4 beta 7/LPAM‑1 in direct ELISAs. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Vedolizumab. This product is for research use only.

Source

Recombinant Monoclonal Human IgG₁ Clone # Hu117

Purification

Protein A or G purified from cell culture supernatant

Immunogen

Human Integrin alpha 4 beta 7/LPAM‑1

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Flow Cytometry

0.25 µg/10⁶ cells

See below

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Flow Cytometry

View Larger

Detection of Integrin alpha 4 beta 7/LPAM‑1 in Human PBMC by Flow Cytometry. Human PBMC were stained with (A) Human Anti-Human Integrin a4 beta 7/LPAM-1 (Research Grade Vedolizumab Biosimilar) Monoclonal Antibody (Catalog # MAB10078) or (B) no primary antibody, followed by anti-Human IgG APC-conjugated Secondary Antibody (Catalog # F0135) and Mouse anti-Human CD3 PE-conjugated Monoclonal Antibody (Catalog # FAB100P). View our protocol for Staining Membrane-associated Proteins.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Integrin alpha 4 beta 7/LPAM-1

Vedolizumab is a biosimilar that binds and blocks binds to integrin alpha 4 beta 7. This product can be used in flow cytometry or various assay formats to block or measure integrin alpha 4 beta 7.

Entrez Gene IDs

3676 (Human); 16402 (Mouse)

Alternate Names

269C wild type; CD49 antigen-like family member D; CD49d antigen; CD49d; CD49d/beta7; CD49Dantigen CD49D, alpha-4 subunit of VLA-4 receptor; IA4; Integrin alpha 4 beta 7; integrin alpha 4; integrin alpha-4 subunit; integrin alpha-4; Integrin alpha-IV; integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor); LPAM1; LPAM-1; MGC90518; very late activation protein 4 receptor, alpha 4 subunit; VLA-4 subunit alpha

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for Human Integrin alpha 4 beta 7/LPAM-1 (Research Grade Vedolizumab Biosimilar) Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

2 Citations: Showing 1 - 2
Filter your results:

Filter by:

Biological Therapy in Inflammatory Bowel Disease Patients Partly Restores Intestinal Innate Lymphoid Cell Subtype Equilibrium
Authors: Brecht Creyns, Inge Jacobs, Bram Verstockt, Jonathan Cremer, Vera Ballet, Roselien Vandecasteele et al.
Frontiers in Immunology
Rotavirus A Inoculation and Oral Vitamin A Supplementation of Vitamin A Deficient Pregnant Sows Enhances Maternal Adaptive Immunity and Passive Protection of Piglets against Virulent Rotavirus A
Authors: J Chepngeno, JO Amimo, H Michael, K Jung, S Raev, MV Lee, D Damtie, AO Mainga, AN Vlasova, LJ Saif
Viruses, 2022-10-26;14(11):.
Species: Porcine
Sample Types: Whole Cells
Applications: Flow Cytometry

FAQs

Does this Biosimilar antibody have the same sequence as the therapeutic antibody?
- The Biosimilar antibody has the same variable region and constant region sequence as the therapeutic antibody, except for Catalog numbers MAB9677, MAB9575, MAB9577, MAB9589, and their conjugates. These four antibodies have the same variable region as the Biosimilar, but not the same constant region.
What is a Biosimilar antibody?
- A Biosimilar antibody is a non-therpeutic, recombinantly-expressed antibody which has the same sequence as the corresponding therapeutic antibody. It is for research use only. The nomenclature of the Biosimilar antibody includes the name of the therapeutic antibody. For example, Catalog # MAB9577 is called Human EGFR (Research Grade CetuxiMab Biosimilar) antibody.
What is the epitope of Human Integrin alpha 4 beta 7/LPAM-1 (Research Grade Vedolizumab Biosimilar) Antibody, Catalog # MAB10078?
- We have not mapped the epitope of this Biosimilar antibody, but the variable sequence is the same as the therapeutic antibody Vedolizumab. According to the following literature, Vedolizumab binds to the extracellular portion of Integrin beta 7: https://academic.oup.com/ecco-jcc/article/10/12/1437/2706991, and https://rupress.org/jcb/article/196/1/131/36697.